Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dissolvable heart stent could replace permanent implants

NCT ID NCT06919562

Disease control Sponsor: Albert Schweitzer Ziekenhuis, Netherlands Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of heart stent that dissolves over time, unlike permanent metal stents. The trial will enroll 117 people with stable coronary artery disease to see if the new stent, placed with special imaging guidance, works safely and effectively. The goal is to reduce long-term problems like inflammation and make future heart surgeries easier.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MeRes100 thin-strut bioresorbable scaffold
What this could lead to
If successful, this could lead to a safer way to open blocked heart arteries that dissolves over time, potentially reducing long-term complications from permanent stents.
What could go wrong
This is a small, early feasibility study (117 people) testing a new device and technique. The scaffold may still cause blood clots or fail to perform as well as current standard stents.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 117 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with obstructive stable coronary artery disease

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Stable coronary artery disease with one or more significant epicardial stenosis in native coronary arteries suitable for OCT or IVUS-guided PCI with BRS implantation. 2. Subject must be at least 18 years of age 3. Written consent to participate in the study Exclusion Criteria: 1. Culprit lesions in the setting of acute coronary syndrome. 2. Lesions with severe calcification. 3. Lesions in a coronary artery with severe tortuosity. 4. Left main coronary artery lesions. 5. Bifurcation lesions. 6. Ostial lesions. 7. Lesions with a difference in proximal and distal reference diameter of \>0.5 mm by visual judgement of the coronary angiogram by the treating operator. 8. Treatment of in-stent restenosis or stent thrombosis. 9. History of definite stent thrombosis. 10. Lesions in coronary artery bypass grafts. 11. Lesions not suitable for OCT or IVUS catheter delivery and imaging, e.g. due to tortuosity or distal localisation. 12. Creatinine Clearance ≤ 30 ml/min/1.73 m2 as calculated by MDRD formula for estimated GFR. 13. Contraindication to dual antiplatelet therapy with aspirin and a P2Y12 inhibitor or (if indicated) NOAC and P2Y12 inhibitor. 14. Planned non-deferrable major surgery after PCI. 15. Known comorbidity associated with a life expectancy \<1 year. 16. Unable to understand and follow study-related instructions or unable to comply with study protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary arterial disease (CAD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary arterial disease (CAD) Percutaneous coronary intervention (PCI)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Albert Schweitzer ziekenhuis

    RECRUITING

    Dordrecht, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.